Revolution Medicines just announced a result that would have seemed impossible a decade ago: a daily pill that nearly doubles survival for patients with advanced pancreatic cancer. The drug, daraxonrasib, targets KRAS—the genetic switch that drives over 90% of pancreatic tumors—by solving a puzzle that scientists once considered unsolvable.
For generations, pancreatic cancer has been one of the deadliest diagnoses. About 97% of patients diagnosed with metastatic pancreatic cancer between 2015 and 2021 died within five years. The disease's lethality stems partly from its silence: it rarely causes noticeable symptoms in early stages, and there are no effective screening tests. By the time patients experience yellowing of the skin, abdominal pain, or other warning signs, the cancer has often already spread to other organs, making treatment far more difficult.
The core problem is genetic. The KRAS gene, which codes for proteins that act as biological switches controlling cell growth, is mutated in more than 90% of pancreatic tumors. When mutated, this switch becomes permanently stuck in the "on" position, commanding cancer cells to multiply endlessly. For decades, scientists considered KRAS undruggable because the protein's surface is exceptionally smooth, lacking the molecular pockets that standard drugs need to bind to and block the signal.
Daraxonrasib overcomes this obstacle through an elegant biological trick. Rather than attacking KRAS directly, the drug attaches to a molecule called cyclophilin A, which helps fold proteins into their working shapes. This complex then binds to the active KRAS protein and shuts down its ability to signal cancer cells to keep dividing. Patients take it as a daily oral medication—a significant improvement over toxic chemotherapy regimens.
The clinical evidence is striking. Revolution Medicines presented Phase 3 trial results in May 2026 from 500 patients with metastatic pancreatic cancer who had already received prior treatment. Compared to standard chemotherapy, daraxonrasib nearly doubled overall survival from 6.7 months to 13.2 months. The drug reduced the risk of death by 60%—a margin that signals genuine progress against a disease that has resisted effective treatment for so long.
Side effects are not trivial. A prominent skin rash affected more than 86% of patients in the study, and many experienced painful swelling and sores inside the mouth, diarrhea, nausea, and vomiting. Yet daraxonrasib's tolerability advantage over chemotherapy is substantial: patients were far less likely to stop treatment due to severe side effects, and they reported improved quality of life with reduced pain—a meaningful distinction for people facing such a serious diagnosis.
This breakthrough represents a fundamental shift in how pancreatic cancer might be treated. For years, the disease relied on chemotherapy as a blunt instrument, killing rapidly dividing cells indiscriminately and causing widespread collateral damage. Daraxonrasib offers precision where there was only broad destruction. The results suggest that targeting the specific genetic driver of pancreatic cancer, rather than simply poisoning fast-growing cells, offers a path forward that both extends survival and preserves quality of life.